EXIT-CVD project launches 22 clinical studies to transform heart disease care across Europe.

The EXIT-CVD consortium, led by University Medical Center Groningen and Royal Philips, has launched a five-year research project involving 22 clinical studies and over 14,000 patients across 17 European countries. The project aims to transform cardiovascular care by focusing on early detection, personalized interventions, and advanced therapies to prevent disease progression and improve patient outcomes. With a budget of EUR 27.6 million co-funded by the EU, the initiative also emphasizes equitable access to innovations, addressing socioeconomic and gender-related gaps. Patient enrollment begins this month, marking a significant step toward more integrated and effective cardiac care in Europe.

Koninklijke Philips NV (PHG) is involved in the EXIT-CVD consortium's cardiovascular research. On Pluang, PHG trades at USD 25.28 with a 1-day gain of 1.12% as of Oct 15, 2026 15:11 WIB. The stock's market cap stands at $24.24 billion, reflecting investor interest in its health sector innovations.